

Contents

<i>Preface</i>	v
<i>Table of Cases</i>	xi
<i>Table of Statutes</i>	xxi
Introduction	1
1. Medicinal Product Liability in Context	4
I. Introduction	4
II. Historical Background: A Special Case? The Unique Characteristics of Medicinal Products	4
III. Position Under the Product Liability Directive and the Consumer Protection Act 1987.....	6
IV. Vaccine Damage	10
V. European Pharmaceutical Product Liability Regimes.....	12
A. The United Kingdom.....	12
B. Germany.....	12
C. Sweden, Finland and Norway	14
VI. Reform	14
VII. Conclusion.....	16
2. Defective Medicinal Products in the US and UK: An Overview	18
I. Introduction	18
II. Defective Medicinal Products in the US.....	18
III. Defective Medicinal Products in the UK	19
A. Definition of Defect.....	19
B. Consumer Expectations and Risk–Utility.....	20
C. Expectations of ‘Persons Generally’	21
D. Circumstances Taken into Account in Assessing Defectiveness.....	23
E. The Defect Taxonomy	32
IV. Conclusion	37
3. Design Defects and Medicinal Products	38
I. Introduction	38
II. Design Defects and Pharmaceutical Products: The US Experience.....	39
A. Comment K.....	39
B. Third Restatement	42
III. Design Defects and Pharmaceutical Products Under the Product Liability Directive	45
A. General	45
B. What is a Medicinal Product Design Defect?.....	45

C.	The Approach for Determining Whether a Medicinal Product's Design is Defective: Consumer Expectations v Risk–Benefit; Cost–Benefit; Net Benefit	46
D.	Relevance of Risk–Benefit to Determining Design Defectiveness: The Member States' Jurisprudence	48
IV.	Reform: A Net Benefit Approach to Drug Design Defects or Combined Consumer-Expectations Risk–Utility.....	50
A.	Net Benefit Approach to Drug Design Defects	50
B.	Combined Consumer-Expectations Risk–Utility.....	51
V.	Conclusion	52
4.	Warning and Instruction Defects and Medicinal Products.....	54
I.	Introduction	54
II.	Warning and Instruction Defects and Pharmaceutical Products: The US Experience.....	54
A.	Main Form of Liability	54
B.	Use of Negligence Principles	55
C.	Adequacy.....	58
D.	Learned Intermediary Doctrine	60
III.	Warning and Instruction Defects and Pharmaceutical Products Under the Product Liability Directive	67
A.	A Fault-based Form of Liability	67
B.	Impossibility of Warning: Undiscoverability or Unknowability of Risk Versus Foreseeability of Risk.....	69
C.	Unforeseeable Injuries: Is There a Role for the Article 7(e) Defence in Failure to Warn Claims?.....	71
D.	Adequacy.....	73
E.	Learned Intermediary Doctrine	74
F.	The Requirement of Causation	77
IV.	Conclusions.....	82
5.	Causation, Risk and Epidemiological Evidence in Medicinal Product Liability Litigation: Law's Coming of Age	84
I.	Introduction	84
II.	Reconciling the Standards of Proof in Law and Science in the UK.....	88
A.	Evidence of Causation for Purposes of Science and for Purposes of Law	88
B.	'Doubling of Risk' Theory	89
C.	Association Versus Causation	95
D.	Teaching the Court the Epidemiology	99
E.	The Statistical Chance/Personal Chance Dichotomy.....	102
F.	Overcoming the Statistical Chance/Personal Chance Dichotomy: Statistical Refining Mechanisms Using Specific Risk Factors	104
III.	Conclusions.....	111
6.	The Rise and Fall of the MMR Litigation: A Comparative Perspective	114
I.	Introduction	114
II.	Background: The Vaccines and Autism Controversy.....	115

III.	UK MMR Litigation.....	115
A.	Legal Aid Funding and Establishment of Group Litigation.....	115
B.	Withdrawal of Funding and Dissolution of Group Litigation	116
IV.	The US Omnibus Autism Proceeding Test Cases	117
A.	The Omnibus Autism Proceeding (OAP)	117
B.	The First Three Test Cases and the Petitioners' First Theory	119
C.	The Second Three Test Cases and the Petitioners' Second Theory	123
D.	Implications of the Test Cases.....	125
V.	A French Comparison: The Liberal French Approach to Hepatitis B Vaccine and Demyelinating Diseases Using Presumptions of Causation	128
VI.	MMR and the General Medical Council	132
A.	The Professional Conduct Hearing	132
B.	Consequences of the Professional Conduct Hearing	133
VII.	Conclusion	134
7.	Regulatory Compliance and Medicinal Product Liability.....	136
I.	Introduction	136
II.	Compliance with Common Practice Regulatory and Statutory Standards	136
A.	Compliance with Common Practice of the Pharmaceutical Industry	136
B.	Compliance with Statutory Requirements	138
III.	Defect Attributable to Mandatory Statutory or Community Requirements	144
IV.	Federal Preemption and Prescription Drugs.....	145
A.	Nature and Importance of the Doctrine.....	145
B.	The Preemption Taxonomy	145
C.	Presumption Against Preemption	146
D.	Emergence of an FDA Preemption Policy.....	147
E.	Rejection of the FDA Preemption Policy: <i>Wyeth v Levine</i>	148
F.	Emergence of a Two-Tier Drug Liability System: <i>PLIVA v Mensing</i>	153
V.	A Regulatory Compliance Defence for Medicinal Products.....	158
A.	Introduction.....	158
B.	Arguments in Favour of a Defence.....	159
C.	Arguments Against a Defence.....	161
VI.	Conclusion.....	166
8.	The Development Risk Defence and Medicinal Products	168
I.	Nature and Scope of the Defence	168
A.	Introduction.....	168
B.	Background and Definition	169
C.	Some Criticisms of the Statutory Wording.....	171
D.	Development Risk and the State of the Art Defence.....	172
E.	Optional Nature of the Defence	174
F.	Member States Which have Derogated from the Defence	174
G.	The Relevant Time at Which to Apply the Test.....	175

II. Infringement Proceedings in the European Court of Justice:	
<i>Commission v United Kingdom</i>	176
A. Initial Stages	176
B. Advocate General's Opinion	177
C. The Judgment of the European Court of Justice.....	179
III. European Commission Reform Proposals	182
A. Green Paper.....	182
B. Second Commission Report and Fondazione Rosselli Study	182
C. Report on Product Liability in the European Union for the European Commission (February 2003).....	184
D. Third and Fourth Commission Reports	184
IV. Defects Which Might be Expected to be Discovered	185
A. General Observations	185
B. Discoverability and Economic Feasibility	186
C. Discoverability of Unknown and Unknowable Defects	187
D. Defects Hidden from View by Limited Scientific and Technical Knowledge.....	187
V. The Meaning and Implications of Scientific and Technical Knowledge.....	188
A. General Observations.....	188
B. The Constituents of Knowledge	189
C. Knowledge in the Context of an Adverse Drug Reaction	191
D. Knowledge and Accessibility	192
E. The Example of Thalidomide	193
VI. Defects Which are Known of, but Undetectable in any Particular Case.....	194
A. Introduction.....	194
B. Defects Which are Undetectable	195
C. Comparative Jurisprudence	198
D. Conclusions.....	201
VII. Conclusion.....	202
9. Conclusion	205
<i>Index</i>	211